Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.89 USD | -0.46% |
|
-8.47% | +204.18% |
May. 31 | Jasper Therapeutics, Inc. to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 | CI |
May. 20 | Transcript : Jasper Therapeutics, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+204.18% | 362M | |
+48.79% | 781B | |
-7.23% | 350B | |
+19.43% | 330B | |
+7.18% | 293B | |
+16.89% | 248B | |
+0.16% | 221B | |
+11.65% | 217B | |
+4.53% | 162B | |
-3.92% | 157B |
- Stock Market
- Equities
- JSPR Stock
- News Jasper Therapeutics, Inc.
- Oppenheimer Adjusts Jasper Therapeutics Price Target to $8 From $21, Maintains Outperform Rating